Much effort has been invested in studying how natural products are biosynthesized, and great advances have been made in understanding how these compounds acquire their structural complexity and biological activities. In recent years, significant progress has been made due to the devoted efforts of scientists in this field and to technological advancements. Numerous details, applications, and innovative findings have been elucidated by scientists using biochemical, genetic, and molecular biological approaches. Here I present a comprehensive overview of highly valued biosynthetic proteins, polyketide synthase and nonribosomal peptide synthetase. I begin with ''Diels-Alderase'' a captivating enzyme that has the ability to catalyze a Diels-Alder reaction valued by chemists for its usefulness in chemical synthesis. A handful of these enzymes have been characterized and chemically authenticated. The most well understood enzyme of this category is macrophomate synthase. Secondly, I focus on the polyketide and nonribosomal peptide biosynthetic pathways and the enzyme assembly for producing its metabolite. Many important natural products are produced by this biosynthetic pathway as secondary metabolites, such as erythromycin, rifamycin, and FK520, as antibiotics and an immunosuppressive, respectively. I conclude with a discussion of nonribosomal peptides and their mechanistic pathways. Special attention will be devoted to de novo production of echinomycin in a heterologous manner, the earliest example of totally engineered biosynthesis of the biologically active form of a nonribosomal peptide host in Escherichia coli.
Key words: Diels-Alder reaction; biosynthesis; polyketide synthase; nonribosomal peptide synthetase; de novo production Many secondary metabolites have been isolated and characterized from a variety of natural sources, such as bacteria, fungi, and plants. They are of high interest and importance because they often exhibit a broad spectrum of biological activities. Their remarkable properties can be attributed to their structural complexity and diversity. Each biosynthetic enzyme catalyzes a reaction corresponding to its structure, providing an important compound upon completion of the biosynthetic pathway. [1] [2] [3] [4] [5] Chemists interested in the field of biosynthesis are attracted to carbon-carbon bond forming enzymes that possess the ability to produce a molecule's skeletal structure. There are two categories of enzymes that are capable of catalyzing reactions requisite to the formation of a compound's backbone core structure. Although it is relatively small, one notable protein has been found to biosynthesize a compound's core structure though it possesses only a single active site. At the opposite end of the spectrum, an enzyme known to catalyze a multi-step reaction mechanism requires multiple catalytic domains. These domains biosynthesize polyketides (PKs) and nonribosomal peptides (NRPs), and are commonly described as modular enzymes, boasting a molecular weight of a few hundred kDa. They assemble complex secondary metabolites using a starting unit and simple building blocks as substrates. This review focuses on the two classes of enzymes just mentioned, and discusses the detailed reaction mechanisms of a small molecular weight enzyme possessing a single active site. It also covers examples of engineering the complex processes of assembling these macromolecules, the intrinsic challenges of engineering natural product biosynthesis, and its industrial applications in drug discovery.
I begin by examining the former of the two enzymes: an enzyme catalyzing a cycloaddition, which is highly useful, since it is very difficult to construct cyclic compounds by means of chemical synthesis while controlling regio-and stereoselectivities in the molecule. In particular, a Diels-Alder reaction progresses to completion under mild conditions devoid of the intermediate isolated form due to its transition state and geometry, which involves -orbitals. The reaction progresses in a concerted fashion through an intra-or an intermolecular interaction via unsaturated bonds. Hence, this reaction has been used in chemical synthesis and in studies of biosynthetic mechanisms in bioorganic chemistry. It has been proposed that many natural products are subjected to this reaction as they are biosynthesized, but only two examples of biotransformation have been described in detail, through reaction mechanism studies using purified natural enzymes that catalyze a Diels-Alder reaction.
Worthy of mention are two enzymes previously reported as Dield-Alder reaction catalyzing enzymes based on observed cycloaddition reactions. One is the lovastatin nonaketide synthase (LNKS), credited with producing lovastain's decalin core structure via a DielsAlder reaction, which was originally reported by Hutchinson and Vederas et al. (Scheme 1b). 6, 7) Although LNKS appears capable of biosynthesizing dihydromonacolin L via an endo Diels-Alder reaction, in vitro assays revealed that such biosynthesis would require an extra enzyme, LovC. Hence, no study has unambiguously demonstrated the ability of LNKS to catalyze a Diels-Alder reaction as a single-enzymatic reaction. A second enzyme, studied extensively by Watanabe et al. to determine its detailed reaction mechanism and crystal structure is the macrophomate synthase. [8] [9] [10] [11] [12] [13] [14] [15] In the following concentrate on macrophomate synthase and the question how to determine the presence of a ''Diels-Alderase'' in nature, [16] [17] [18] following this introductory section.
I also consider the modular biosynthetic enzymes in detail. These modular enzymes, which are responsible for producing important biologically active compounds, some of which are in clinical trials and some of which have become indispensable drugs in clinical and commercial use, such as FK506 (an immunosuppressant), lovastatin (a cholesterol-lowering agent), and taxol (an antitumor agent) (Fig. 1) . However, it has been a difficult process for many natural products to make their way to the market and become drugs when productivity from natural sources is low, or because many organisms, including the vast majority of soil and marine bacteria, are not amenable to artificial cultivation. All natural products are conventionally produced by means of biosynthetic proteins catalyzing synthetic pathways step by step, followed by metabolism. Hence, expression of biosynthetic genes encoding the enzymes responsible for producing a target compound makes it possible to provide the compound at substantial yield using an efficient expression system. Furthermore, such a system should make it possible to produce marine natural products originally isolated from marine organisms that are nearly impossible to cultivate using much simpler culture conditions. Recently, much effort has been concentrated on developing expression systems for the heterologous production of complex natural products using streptomycete, [19] [20] [21] [22] [23] yeast, 24) and E. coli.
25-29)
E. coli is used in molecular cloning in genetics, molecular biology, microbiology, and the generation of recombinant proteins in biological chemistry and structural biology in quantities sufficient for protein characterization. Scientists in various disciplines have relied on E. coli to expand their scope by taking advantage of this bacterium's fast life cycle. In addition, knowledge of its complete genome and extensive understanding of its metabolic pathways has greatly reduced uncertainty for researchers. This organism is a powerful tool that has reached across to numerous other research fields and has become vital to their advancement.
To conclude this review, attention will be given to heterologous production of NRP antibiotics in E. coli, a system developed in our laboratory. Innovative approaches to engineering biosynthesis of this class of natural products to broaden and strengthen the potential diversity of such compounds is also explored. Finally, I will present some prospective applications in drug discovery using the biosynthesis of natural products, and the mention some obstacles that must be circumvented in future work and some findings in natural product chemistry.
I. Macrophomate Synthase, the Natural Diels-Alder Reaction Catalyzing Enzyme
Discovering novel enzymes and deciphering their mechanisms of enzymatic reaction is an arduous undertaking that requires an overlap of technologies from biochemistry, natural product chemistry, molecular biology, and sometimes structural biology. Here I discuss some approaches to obtaining evidence for the existence of a Diels-Alderase in nature. Previous reports have described the biotransformation of conjugated pyrones to corresponding benzoic acids in the biosynthetic pathway of a phytopathogenic fungus, Macrophoma commelinae. [30] [31] [32] Based on labeling of experimental results and as predicted by chemical structures isolated from the strain, one of two potential substrates appeared to be 2-pyrone (1) in this bioconversion, shown in Scheme 1c; the second substrate, however, was not identified in a series of experiments. 33, 34) Watanabe et al. suspect that enzymatic conversion of the two substrates involved a Diels-Alder reaction affording benzoic acid as a cycloadduct. Hence, they set out to locate an enzyme, natural Diels-Alderase, responsible for this biosynthesis. 8) We began with attempts to identify a substrate essential to the biosynthetic step through the use of a cell-free extract from a fungal culture and the addition of 1 prior to harvesting the cells to determine whether there would be an upregulation of this metabolic pathway. Low-level production of macrophomic acid (2) was detected by this approach when supplemented with 1, but productivity was not significant, and did not increase under the above conditions because the assay requires a limited level of unidentified substrate and co-factors in the cell-free system. While screening numerous compounds in the hope of obtaining a complementary enzymatic reaction using a cell-free system, we were finally able to identify a substrate, oxaloacetic acid, as a dienophile that employs the Diels-Alder reaction co-factored with an obligatory Mg 2þ .
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These findings enabled us to purify an enzyme that we named macrophomate synthase. This enzyme catalyzed the bioconversion of 1 to 2 using oxaloacetic acid along with Mg 2þ , speculatively involving the Diels-Alder reaction. By biochemical procedures, we were able to determine its N-terminal and partially to sequence the protein. With this information, molecular cloning of a cDNA coding the enzyme was completed and it was overexpressed in E. coli.
11) An ample quantity of highly pure protein provided us with many opportunities to characterize the enzyme by in vitro assays. When testing the substrate tolerance of this enzyme using 3 as a substrate analog, we were not able to isolate a corresponding benzoic acid, but rather isolated an unexpected bicyclic product, 4, from the reaction mixture. 10, 12) Obtaining the chemical structure of 4 paved the way to conclusively deciphering a reaction mechanism for the enzyme. To understand how 4 is formed and to verify it as a shunt product of the DielsAlder reaction void of the original substrate 1, we chose the absolute configuration of 4 strategically and then determined the stereochemical course of the complete reaction using deuterium-labeled oxaloacetic acid, which we prepared using an enzyme coupled reaction. 13) The ability of this enzyme to catalyze the Diels-Alder reaction was confirmed because a set of bicyclo[2.2.2]-intermediate analogs that we designed and synthesized were observed as its competitive inhibitor. 14) These inhibitors were designed to mimic a proposed intermediate of the enzyme, on the assumption that it is able to catalyze the Diels-Alder reaction. Finally, based on the reaction mechanism for 4, illustrated in Scheme 2, and kinetic analysis of the enzyme affording pyruvate enolate, 2, and the structure of 4, showing two carboncarbon bond formations that are highly efficient steps in this enzymatic reaction, macrophomate synthase is undoubtedly the first enzyme known to catalyze a Diels-Alder reaction responsible for converting 1 to 2. Recently, Hilvert and his co-workers elucidated the final reaction step, which progressed in a stepwise fashion involving a Diels-Alder reaction followed by decarboxylation, and concluding with a dehydration reaction, as illustrated in Scheme 1d. 35) The crystal structure of this protein visually revealed not only the locations of for substrate 1, pyruvate, and Mg 2þ , but also an interactive network system between the substrate, co-factor, and amino acid residues in the active site. 15) This model illustrates an overlapping molecular orbital between two substrates captured in the enzyme, which is indicative of a Diels-Alderase. 
II. Deciphering the Biosynthetic Code Responsible for Producing Polyketide and Nonribosomal Peptide
Since the 1990s, many gene clusters have been isolated and identified from bacteria responsible for secondary metabolites such as PKs, 36, 37) NRPs, 38) terpenes, 39) and aminoglycosides. 40, 41) Numerous yet powerful molecular biological techniques were also being developed. These findings were a genetic contribution to the next generation's drug discovery. Recent papers have presented characteristic mechanisms of biosynthetic proteins coded in gene clusters and elaborate production of natural products by the expression of biosynthetic genes in a heterogous host. It is now anticipated that these production systems will provide more efficient methods of obtaining useful compounds and displace our dependence on natural products from their natural hosts.
Erythromycin, rifamycin, and vancomycin are examples of clinically important natural products isolated from streptomycete as secondary metabolites exhibiting notable biological activity as antibiotics ( Fig. 1) . Their notoriety as potent antibiotics has encouraged chemists to synthesize them chemically along with some of their derivatives for further studies in the hope of improving their pharmacological properties. In recent years, many more biosynthetic genes have been isolated and identified from additional strains that are responsible for producing valuable molecules, adding to the list of compounds mentioned above. Commonly, these complex natural products are synthesized by many biosynthetic proteins that are encoded in many genes located at a single position and clustered together on a chromosomal or linear-plasmid DNA, called a gene cluster. Based on sequence analysis of extracted gene clusters, it was found that erythromycin and rifamycin are both synthesized by modular polyketide synthase (PKS), and that vancomycin is synthesized by nonribosomal peptide synthetase (NRPS). 42, 43) The mechanism of chain elongation, carbon-carbon bond formation, in backbone biosynthesis of a compound by modular PKS is similar to fatty acid synthase. The gene cluster coding for PKS is a large modularlyorganized enzyme responsible for their biosynthesis (Fig. 2a) . A single module of the enzyme ranges in size from 120 to 180 kDa, and possesses the ability to extend a carbon chain independently using a single building block. Similarly, NRPS is large and is genetically encoded in a manner similar to PKS, and is also comprised of multi-domain complexes (Fig. 2b) . It catalyzes a reaction for peptide bond formation generating the NRP core structure. The compulsory biosynthetic pathway components have been discovered and are known to initiate production of these compounds by manufacturing the starter unit and building blocks, which include the propionyl-, methyl-and ethylmalonyl-CoA necessary to a variety of PKs. 44) Each PKS or NRPS can then be converted efficiently from inactive apo-to phosphopantetheinyl-containing holo-acyl carrier protein (ACP)/thiolation (T) forms for the elongation of PK or NRP assembly. Moreover, each module recognizes an appropriate building block, makes a chain elongation, and controls the stereochemistry biosynthesizing the core structure, followed by programmed biosynthetic array.
It is believed that swapping a module from another biosynthetic cluster, changing the order of the biosynthetic modules, and deleting a domain within the module will provide a rationally tailored molecule, allowing one to design and produce them in the same manner as one would via chemical synthesis. In fact, rationally engineering modular PKSs has provided a divergence of polyketide scaffolds. Thus it is possible to generate diverse, novel compounds with desirable pharmacological profiles by rational engineering of their biosynthetic machinery. Manipulation of genes and assembly of biosynthetic clusters for expression in a heterologous host such as E. coli has been reported. Using E. coli as a heterologous host takes advantage of its availability and of well-established molecular biological techniques for genetic and metabolic manipulation. In addition, the ease of fermentation of this bacterium makes if particularly suitable for the overproduction of natural products. Its robust tolerance of exogenous proteins and fast life cycle should also promote engineering efforts. Means of large-scale protein production should also facilitate detailed biochemical characterization of the biosynthetic pathway and make it possible to conceive a scaffold for a rational approach to optimizing the pathway and modifying the production of exogenous natural products and their analogs. However, biologically active forms of complex natural products produced by PKS and NRPS cannot be obtained using E. coli transformed with complete biosynthetic machinery to allow de novo production. Because such complex natural products are synthesized by numerous enzymes and the size of each PKS and NRPS module is large, ranging from 4 to 6 kb in length, it is very difficult to incorporate every gene into a plasmid vector for the expression and heterologous production of natural products with an E. coli-based system. We achieved heterologous production of NRP antibiotics, echinomycin and triostin A, in E. coli in our laboratory (Fig. 3) . Below is a summary of our recent experimental results for transplantation of NRP echinomycin gene cluster from its natural host into E. coli making possible the development of an E. colibased host system for unmitigated engineered biosynthesis of natural products. 45) III. Rifamycin Intermediate P8/1-OG Production in E. coli
Rifamycins and other ansamycins are a PK class of natural products containing a benzoic or naphthalenic chromophore bridged by an aliphatic PK chain that terminates at the chromophore with an amide linkage. The biosynthetic pathway for ansamycin type PK enlists 3-amino-5-hydroxybenzoic acid (AHBA) to serve as a starting unit for the assembly of these molecules. In order to investigate the assembly of intermediary rifamycin, 2,6-dimethyl-3,5,7-trihydroxy-7-(3 0 -amino-5 0 -hydroxyphenyl)-2,4-heptadienoic acid (P8/1-OG) (Scheme 3), Khosla introduced two powerful technologies to express multiple open reading frames (ORFs) in the expansive biosynthetic gene cluster coding megasynthase, documented to biosynthesize the PK backbone structure.
To facilitate the reconstitution of a biosynthetic operon for the expression in E. coli, seven biosynthetic genes responsible for the production of AHBA must be reconstituted for the bacterium to govern the expression of this gene cluster. 27) Each ORF calls for a ribosome binding site (rbs) for successful expression in an E. colitranslation system, and the reconstituted operon requires promoter for transcription in E. coli. Seven genes from the rifamycin gene cluster were cloned into pET28 expression vector. By taking advantage of the compatibility between restriction endonuclease XbaI and SpeI sticky ends to construct a single vector, individual ORF cassettes with rbs (XbaI-SpeI) were assembled as a polycistronic expression plasmid.
In addition, the significant protein expression levels of these modular genes in E. coli require that the rifA that codes for the first polypeptide of rifamycin PKS be stretched across 15 kb of DNA. The molecular weight of the posttranslational product is estimated to be 0.53 megadalton. Expression of the ORF in E. coli, engineering rifA, the loading domain, and module 1, and module 2 and 3, requires that they be expressed separately as two polypeptides. Responsible for biosynthesizing aglycon erythromycin, 6-deoxyerythronolide B synthase has been found to contain two pairs of intermodular linkers. 46) These linkers are believed to act as a glue augmenting binding affinity between module 2 and 3 and module 4 and 5 in the 6-deoxyerythronolide B biosynthetic assembly line. It has also been recognized that antiparallel helical interactions between intermodular linkers play a part in the chain transfer of a linear PK from the polypeptide to a downstream polypeptide. In regard to the functional reconstitution of RifA protein, a pair of linkers were fused to the C terminus of Rif module 1 and the N terminus of Rif module 2, which were then cloned into a single plasmid.
The two plasmids were introduced into an E. coli strain, BAP1, which was engineered by Khosla and his co-workers.
25) The genetically engineered bacterium was found to produce the expected intermediate P8/1-OG at a final yield of 2.5 mg per liter of culture. The realization of an E. coli-based expression system by a plasmidborne operon of the complex biosynthetic pathway and functional expression of the mega-gene responsible for producing PK and NRP core structures was thus confirmed.
IV. Echinomycin, a DNA Bis-Intercalating Nonribosomal Peptide Antibiotic
Echinomycin is an NRP isolated from an assortment of bacteria, including Streptomyces lasaliensis, and it belongs to a large family of quinomycin antibiotics. 47) As its name implies, this class of natural products possesses bicyclic aromatic quinoxaline or quinoline chromophores attached to the dimerized cyclic peptide core structure. Interest in this group of natural products stems from its potent antibacterial, anticancer, and antiviral activities. Nearly all of the compounds are potent antibiotics against Gram-positive bacteria via inhibition of DNA-directed RNA synthesis. [48] [49] [50] Echinomycin has also been found to possess a strong cytotoxic effect against a variety of cultured tumor cells. Furthermore, a number of these compounds exhibited nanomolar potency in cytotoxic and antiviral activity assays. 51) All of the observed biological activities, including the differences in biological targets, appear to originate from their powerful, sequenceselective DNA binding capability. As judged by detailed X-ray, NMR structural, and other biophysical studies of these molecules, heteroaromatic planar chromophores, the invariant feature of quinomycin antibiotics, provide these compounds with the ability to bis-intercalate tightly into DNA. [52] [53] [54] In addition, a comparative study of echinomycin and SW-163D [55] [56] [57] [58] found that the type of chromophore in the compounds influences their sequence selectivity. 59) However, the cyclic peptide backbone of these molecules, while providing a rigid framework that holds the chromophores in place for effective DNA intercalation, also plays an important role in determining the binding sequence specificity of these antibiotics, primarily by forming hydrogen bonds with the base moieties in the minor groove. [52] [53] [54] Furthermore, modification of the cross-bridge provides further finetuning of the binding site selectivity of these quinomycin antibiotics. This was illustrated by DNA-binding studies on echinomyicn and its close relative, triostin A. The only structural difference between them is the crossbridge: echinomycin has a thioacetal bridge, whereas a disulfide bond interlinks the triostin A backbone, but the subtle structural differences between the two compounds result in notable differences in their DNA sequence selectivity.
60)

V. Proposed Mechanism of Biosynthesis of Echinomycin
To identify and isolate the echinomycin biosynthetic gene cluster, a cosmid library was constructed using the total DNA obtained from S. lasaliensis. A sequence of the echinomycin biosynthetic pathway involved in quinoxaline-2-carboxylic acid (QXC) and peptide backbone biosyntheses is shown in Fig. 4 and Scheme 4. Based on past findings, L-tryptophan was identified as the precursor to QXC. 61) The predicted functions of the proteins encoded within the gene cluster allowed us to hypothesize and construct the QXC biosynthetic pathway illustrated in Scheme 3. Moreover, we have performed feed studies using (2S, 3S)-and (2S, 3R)-diastereomers that we synthesized as the proposed substrate for Ecm11 of the QXC biosynthetic pathway, and found that only one substrate, (2S, 3S)--hydroxytryptophan, afforded us QXC when fed to S. lasaliensis.
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Thus we were able to establish the absolute configuration of a key intermediate for the biosynthesis of QXC. Plans to decipher this pathway to its entirety are ongoing.
Observation of the peptide core of echinomycin revealed that the cluster contains four intact NRPS modules that are responsible for its assembly. Analysis of the deduced adenylation (A) domain's nucleotide sequence using a web-based guide protocol helped to determine that the first, third, and fourth A domains are capable of recognizing and ultimately activating L-serine, L-cysteine, and L-valine for consecutive addition downstream, respectively. In addition, an epimerization domain in module 1 of the four modules catalyzes the conversion of L-to D-serine, and a methylation domain for N-methylcysteine synthesis in module 3 and one for N-methylvaline synthesis in module 4 were also identified, providing us with additional clues deducing their positions on the assembly line. Furthermore, analysis of reported multi-module NRP systems, such as gramicidin S and enterobactin, suggest that the echinomycin-synthesizing NRPS system is composed of four modules capped off with a thioesterase domain capable of peptide chain homodimerization and cyclorelease (Scheme 5a). Further evaluation of the gene cluster failed to reveal any independent aryl carrier protein (ArCP) in the gene cluster. While we were waiting for the completion and refinement of our sequence, Keller et al. uncovered an adenylation enzyme responsible for transferring QXC to the ArCP of the echinomycin biosynthetic pathway by directly examining the function of purified protein isolated from a separate echinomycin-producing strain, S. echinatus. 63) They found that the echinomycin biosynthetic pathway recruits an ACP of fatty acid synthesis during biosynthesis as a substitute for a putative ArCP. This result parallels our independent sequencing efforts confirming justify the absence of an ArCP in the cluster. 63) With reference to the results published by Keller's group, the fatty acid ACP was isolated from S. lasaliensis, and was later incorporated into our biosynthesis model. Ttriostin A has been recognized as a direct precursor to echinomycin for two decades. Undergoing a radicalproducing reaction, triostin A is converted to echinomycin through the formation of a unique thioacetal bridge, characteristic of echinomycin. 64) It is thought to convert the disulfide bridge in triostin A to a thioacetal bridge in echinomycin via a sulfoniumylide intermidate (Scheme 5b), and data obtained from the DNA sequence for the gene cluster revealed a single enzyme, Ecm 18, that was highly homologous to a known S-adenosyl-L-methionine (SAM)-dependent methyltransferase. To understand the biochemical function of Ecm18, we demonstrated, by means of an in vitro assay, that purified Ecm18 catalyzed the conversion of triostin A to echinomycin in the presence of SAM. Uncovering a single methyltransferase that is capable of biotransforming a disulfide bridge into a thioacetal moiety is perhaps significant.
VI. De Novo Production of Quinomycin Antibiotics in E. coli: Echinomycin and Triostin A
Our main objective here is to engineer E. coli for heterologous NRP biosynthesis using only glucose and simple salts. This should allow for advances in the field of natural products. A system such as the one described should establish an E. coli-based system for efficient production of essential natural products and their analogs using simple and economical carbon and nitrogen sources as ingredients.
To attempt heterologous production of echinomycin in E. coli, we first examined the feasibility of expression of each of the 15 S. lasaliensis genes in E. coli. Once this was confirmed, we assembled the 15 genes into three separate plasmids, allowing each gene to carry its own T7 promoter and rbs. Two restriction endonuclease sites (Xba I and Spe I) were included in a pET vector system, placing the Xba I site on the 5 0 side of the promoter and the Spe I site on the 3 0 side of the terminator. Both Xba I and Spe I produce compatible overhangs, and thus, a promoter-gene-terminator cassette that can ligate into a vector carrying another promoter-gene-terminator cassette(s) can be prepared by Xba I-Spe I double digestion of the cassette and either Xba I or Spe I digest of the vector (Fig. 5) . To insure stable retention of all three plasmids in E. coli, we used the orthogonal origins of replication and three antibiotic resistance genes. Our approach requires multiple monocistronic gene cassettes rather than a single polycistronic gene cassette for the assembly of the multi-gene plasmid constructs. It simplifies plasmid construction and reconstruction, because it eliminates the need to clone each gene in the construct in the same transcriptional direction. Furthermore, the practice of transcribing each gene independently helped to achieve comparable levels of protein production despite the many genes that were incorporated into our plasmids for heterologous expression in E. coli. We attribute these findings to the abundance of mRNA transcribed from our numerous monocistronic cassettes as opposed to using a single polycistronic gene cassette approach which usually leads to incomplete synthesis or unstable mRNA. Also, we believe that our approach improved our ability to incorporate a greater number of heterologous genes into E. coli in a simple, reliable fashion.
Subjecting E. coli strain BL21 (DE3) carrying our three plasmids to an 8-d-long fed-batch fermentation in M9 minimal medium, we purified echinomycin from the culture extract through a series of chromatographic steps to obtain a final yield of 0.3 mg of echinomycin per liter of culture. Furthermore, to demonstrate the ease and effectiveness of modifying our E. coli-based heterologous biosynthetic system, we tailored the echinomycin biosynthetic pathway into a triostin A biosynthetic pathway by modifying our plasmids and removing ecm18. The further modified strain produced the antici-pated compound, triostin A, at a yield of 0.6 mg per liter of culture. Unlike chemical synthesis, our system permits one-pot, hands-free, and easily scalable bioproduction of complex natural products and their analogs in less than 2 weeks, omitting the need for highly-trained organic chemists with sophisticated laboratory expertise. Relative to previous attempts to develop an E. colibased heterologous host system for the biosynthesis of natural products, our results are comparable if not superior to the published results. In fact, we believe that our result was significant for the production of such complex compounds even under fermentation conditions that have not yet been optimized.
Based on our own observations, we expected the efficiency of such demanding transcription and the stability of the lengthy mRNA to be rather low when a polycistronic system was used in the PKS and NRPS systems. In the event, a disproportionate expression level of each of the genes was observed, as expected. This may be due to the fact that the expression level of the genes located farther downstream from the promoter tapers off as a function of distance in this plasmid-borne system. Aside from transcriptional and translational efficiency issues, construction of such plasmids is very demanding and requires technical know-how. In addition to the difficulties of generating plasmids carrying multi-gene inserts, if one is to create a polycistronic cassette one needs to worry about the orientation of the insert, which can be difficult to control. The efficiency of procuring constructs with unidirectional inserts in the same reading-frame decreases rapidly as the number of genes to be inserted increases. Use of multi-monocistronic cassettes can eliminate the need to control the gene's orientation and significantly improve the efficiency of the plasmid construction. Our results confirmed that replacement of the polycistronic cassette with a multi-monocistronic cassette can consistently exhibit high expression levels of all the genes in our construct and facilitate plasmid construction. We believe that these improvements have made de novo biosynthesis of complex natural products possible.
When introducing any exogenous biosynthetic pathway into E. coli, the toxicity of the biosynthetic product can impair the host. This problem can be circumvented by introducing a self-resistance mechanism, conferring resistance without degrading the target compound. In considering the echinomycin biosynthetic pathway, the homology of Ecm16 and daunorubicin resistance-conferring factor DrrC 65, 66) and the similarity between their mode of action for echinomycin and daunorubicin suggests that Ecm16 bequeaths S. lasaliensis non-destructive resistance against echinomycin. We were able to demonstrate that ecm16 conferred echinomycin resistance on BL21 (DE3). Also, omission of ecm16 hampered the growth of the host, suggesting that sufficient amounts of echinomycin and triostin A are unattainable without the aid of ecm16, an echinomycinresistance mechanism.
VII. Challenges in Engineering Natural Product Biosynthesis and Industrial Applications in Drug Discovery
In this section, I present an overview of advances in the engineering of natural product biosynthesis and of technological possibilities in drug discovery in the near future using methods that I have discussed in this review. It is anticipated that biosynthesis of these compounds via heterologous production might make up for the low levels usually isolated from the original host. Today, many commercially available antibiotics are obtained by fermentation technology, and are isolated from soil microbial organisms. These strains are frequently amenable to artificial cultivation under laborious optimizations of culture conditions, and it is possible to isolate a substantial amount of compounds at a level of 10-100 mg per liter of the culture under specified conditions. Although many natural products can be isolated only in trace amounts, they are sometimes significant and exhibit potential activities for clinical use. Due to improvements in analytical instrumentation and purification tools, isolation of low production levels of these molecules is probable. The present findings combined with technological progress in natural products chemistry should offer more opportunities for drug discovery. In order to gain approval for clinical use, potential therapeutic agents must be subjected to numerous studies that include animal studies and clinical trials, which sometimes exhaust 1 kg or so of compound. Moreover, once the compounds pass FDA scrutiny and are approved for market use, pharmaceutical companies must supply the product at competitive low cost. Until recently, there were limited alternatives to chemical synthesis to obtaining adequate supplies of the molecules required for mandated studies. Chemical synthesis of complex natural products, the cost of disposing of environmentally harmful byproducts that are generated during the process, such as organic solvents and heavy metals, and the costs of maintaining a staff of highly knowledgeable and skilled synthetic chemists make this method economically undesirable. Thus, the effort to provide complex molecules by way of chemical synthesis for commercial use has often met with difficulty.
To circumvent limited compound availability and high cost to consumers, many researchers have shifted their focus to identifying and isolating gene clusters that are hypothesized to produce compounds of interest. Possession of a system to express sufficient gene clusters coding for biosynthetic enzymes responsible for synthesizing natural products in a heterologous host should increase the arsenal of important and useful compounds more simply and at lower cost. Additionally, heterologous production should also make possible increases in productivity relative to the original source by appendaging a promoter for upregulation of gene transcription by routine molecular biological manipulation.
Marine natural products include a cornucopia of lead compounds with potent activities, but the inaccessibility and isolation of these compounds make them difficult due to their low titer. Also, the producers of these compounds are frequently unculturable organisms that require special equipment for isolating the marine natural products. Ecteinascidin 743 (ET 743), discodermolide, bryostatin 10, arenastatin A, and dolastatin 10 are examples of marine natural products that are considered last resort lead compounds in nature (Fig. 6 ). Detailed analysis of their chemical structures has facilitated prediction of their biosynthetic pathways and has identified enzymes that may be involved. A gene segment isolated from a marine organism has recently been reported as a portion of the bryostatin biosynthetic gene cluster coding for a PKS-type enzyme. 67, 68) Isolation of the entire gene cluster responsible for biosynthesizing an interesting marine natural product for use with our heterologous production system should provide more opportunities to obtain the molecule. ET 743, a natural product found only in marine organisms, exhibits significant antitumor activity, and has drawn the attention of chemists seeking to synthesize the compound chemically. However, because its structure is extremely complex, complete synthesis of the compound did not afford the yield requisite for further studies and commercial use. Fortuitously, two varieties of NRPSs encoding biosynthetic gene clusters were identified in soil-borne bacteria which were identical to the genes responsible for synthesizing saframycin 69) and safracin, 70) both of which are structurally similar to ET 743. When expressed in a compatible heterologous expression system, these NRPSs might provide analogs of ET 743, along with effective intermediates. This should alleviate the need for stereochemistry control and obviate low-yield reactions that generate the many byproducts of chemical synthesis of ET 743, providing a more desirable titer. If it is possible to isolate the entire biosynthetic gene cluster for ET 743, heterologous production of ET 743 is possible by expression of sufficient genes to synthesize this molecule in an appropriate host. Accordingly, heterologous production of compounds provides valuable insight for future drug discovery in addition to the total chemical synthesis and semisynthesis approaches.
So far, I have reviewed and given details regarding the heterologous production of natural products through expression of the gene clusters responsible for producing them. Next I examine the use of mutagenesis to engineer the biosynthesis of unnatural natural products. Currently, many target natural products are chemically derived from more abundantly available precursors. Alternatively, desired modifications are synthetically introduced into natural products to improve their pharmacological properties and to avoid unfavorable biological activities for commercial distribution. Functional alternation of an enzyme encoded in the biosynthetic gene cluster by the introduction of genetic mutation can also yield analogs of important natural products.
Six things must be considered in order to produce an unnatural analog using mutagenic enzymes. Assembly of a biosynthetic pathway for the molecule is indispensable, biochemical studies of the enzyme by in vitro assay are also essential to understand protein expression, and the stability of the enzyme, the detailed reaction mechanism of the enzyme, substrate tolerance, and sometimes the three-dimensional structure of the protein. Expression of the biosynthetic genes in E. coli should make it possible to purify the protein to close to homogeneity at a higher abundance for use in determining the parameters mentioned above. Once fundamental data have been gathered and the expression of functional mutagenic genes with an agreeable host is confirmed, constructing a target molecule via a plasmid-borne biosynthetic pathway should allow production of natural products, and such an approach can also facilitate the assembly of unnatural natural products. Furthermore, it has been postulated that PKS or NRPS domain swapping of assorted biosynthetic clusters, rearrangement of the modules, or deleting an explicit domain within the biosynthetic machinery can provide rationally tailored molecules, thereby yielding the opportunity to design and produce target molecules in the same manner as via chemical synthesis. 71) In addition, alteration of tailoring enzymes such as hydroxylase, methyltransferase, acyltransferase, and glycosyltransferase can yield novel compounds by fusing diverse substituents or changing the positions of the substituents in an aglycon or backbone core structure.
VIII. Concluding Remarks
In this review, I introduce and examine some perspectives on engineering of biosynthesis for heterologous production of useful natural products and their analogs, with special attention to E. coli.
72) Heterologous production of these complex compounds is superior to chemical synthesis in terms of carbon-carbon bond formation and the dictation of a molecule's stereochemistry. Isolating and completing gene sequences for biosynthetic pathways of interest should be considerably easier in the years to come. Compiling a multitude of gene clusters responsible for the production of noteworthy natural products should demonstrate the production system's usefulness and yield many more examples of heterologous production of complex PKs, NRPs and their analogs.
In addition to microbial sources, important metabolites produced in plants are also of interest. Commonly, many biosynthetic genes responsible for producing plant natural products are not located at a single position and are not clustered together on a chromosome, similarly to bacterial and fungal biosynthetic gene clusters. Hence, it is difficult to locate entire biosynthetic genes for plant metabolites. Taxol, an antitumor agent, is an exemplary plant-derived natural product in clinical use today. Only a fraction of the necessary genes, a terpene cyclase and a cytochrome P450-dependent monooxygenase, 73, 74) from the biosynthetic pathway responsible for producing this compound has been uncovered. Thus far, the complete biosynthetic gene sequence for taxol has not yet been uncovered, and hence is not used in heterologous production. Uncovering the entire biosynthetic genes should make it possible to express them in a heterologous host and to provide the therapeutic agent to consumers at below today's market cost.
I also discuss some disadvantages of heterologous production of complex compounds relative to chemical synthesis. Assembling biosynthetic machinery and introducing a large gene cluster more than 50 kb in length responsible for the production of a complex molecule into expression vectors and transforming them into a host cell for heterologous production are undoubtedly demanding tasks. To circumvent the issue of introducing a long coding region, introduction of the cluster into the chromosomal DNA of a heterologous host with a strong promoter might pave the way to stable expression of the genes as a single copy.
Ultimately, the advancement of biosynthetic engineering in the production of useful natural products and their analogs by heterologous production, as described above, should afford more desirable yield, thereby achieving successful production of countless compounds. This novel platform should facilitate future drug discovery by allowing researchers to generate limitless libraries of potential pharmacophores, and should impact industrial participation in therapeutic research and development.
